Ventricular arrhythmias induced by dasatinib are rare events, but physicians in charge of chronic myeloid leukemia patients should be aware of such potential complications and the need for regular ECG controls during treatment with tyrosine kinase inhibitors.
CITATION STYLE
Spechbach, H., Morel, P., Lorenzini, K. I., Besson, M., Gétaz, L., Sunthorn, H., & Chalandon, Y. (2013). Reversible ventricular arrythmia induced by dasatinib. Clinical Case Reports, 1(1), 20–25. https://doi.org/10.1002/ccr3.5
Mendeley helps you to discover research relevant for your work.